

Ligand-Controlled Synthesis of Azoles via Ir-Catalyzed Reactions of Sulfoxonium Ylides with 2-Amino Heterocycles

Alicia M Phelps, Vincent S. Chan, José G Napolitano, Scott W. Krabbe, Jennifer M Schomaker, and Shashank Shekhar

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.6b00497 • Publication Date (Web): 22 Apr 2016

Downloaded from <http://pubs.acs.org> on April 24, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



Ligand-Controlled Synthesis of Azoles via Ir-Catalyzed Reactions of Sulfoxonium Ylides with 2-Amino Heterocycles

Alicia M. Phelps,[†] Vincent S. Chan,[‡] José G. Napolitano,[§] Scott W. Krabbe,[‡] Jennifer M. Schomaker,^{†,*} and Shashank Shekhar^{‡,*}


[†]Department of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, WI 53706, USA

[‡]AbbVie Inc., Process Research and Development, 1 North Waukegan Road, North Chicago, IL 60064, USA

[§]AbbVie Inc., Discovery Chemistry and Technology, 1 North Waukegan Road, North Chicago, IL 60064, USA

Email Address: Shashank.shekhar@abbvie.com and schomakerj@chem.wisc.edu

Abstract




An iridium-catalyzed method was developed for the synthesis of imidazo-fused pyrrolopyrazines. The presence or absence of a nitrogenated ligand controlled the outcome of the reaction, leading to simple β -keto amine products in the absence of added ligand, and the cyclized 7- and 8-substituted-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine products in the presence of ligand. This catalyst control was conserved across a variety of ylide and amine coupling partners. The substrate was shown to act as a ligand for the iridium catalyst in the absence of other ligands via NMR spectroscopy. Kinetic studies indicated that formation of the Ir-carbene was reversible and the slow step of the reaction. These mechanistic investigations suggest that the β -keto amine products form via an intramolecular carbene N-H insertion, and the imidazopyrrolopyrazines form via an intermolecular carbene N-H insertion.

Introduction


β -Keto sulfoxonium ylides are crystalline, bench-stable compounds that function as precursors to metal-carbene complexes.^{1-3,4,5-9} These metal carbene intermediates are known to insert into X-H bonds (X = N, O, S) to generate molecules of synthetic interest; however, only a

limited number of examples have been reported.^{1,2,10-13,14} In contrast, the insertion of metal carbenes generated from diazo compounds into X-H bonds has been well-documented.¹⁵⁻¹⁸ In many cases, the use of diazo compounds on large scales is challenging, due to safety issues resulting from rapid exotherm upon reaction and the generation of stoichiometric nitrogen gas as a by-product.^{19,20,21,22,23} Sulfoxonium ylides are a more practical alternative to diazo compounds, as they are safer to synthesize and generate only non-volatile dimethylsulfoxide (DMSO) as the by-product of metal-carbenoid formation.³ In fact, sulfoxonium ylides have been employed on a manufacturing scale in the synthesis of the CRTH2 antagonist MK-7246.¹² We are interested in further exploring the chemistry of metal-carbenoids generated from sulfoxonium ylides for the syntheses of pharmaceutically relevant molecules.

Imidazo-fused pyrrolopyrazines act as kinase inhibitors and have been shown to be effective for treatment of oncological and immunological diseases.^{24,25} In a previous report, our research group described the synthesis of azole **3** via reactions of **1** with a series of α -bromo ketones **2**, followed by Boc-deprotection and intramolecular cyclization under acidic conditions (equation 1).²⁶ Although **3** was obtained in good yields, many of the α -bromo ketones utilized were lachrymatory oils that were both challenging to purify and unstable under ambient conditions.^{27,28-30}




An alternative approach to access **3** from readily available, crystalline starting materials can be envisaged through insertion of a metal-carbenoid generated from β -keto sulfoxonium ylide **5** into the N-H bond of 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-amine **4** (equation 2).



Indeed, the N-H insertion product **6** was obtained in moderate yields (40-50%) under conditions similar to that reported by Mangion and co-workers for reactions of aromatic amines

with sulfoxonium ylides (equation 3).^{2,10} In addition to the expected acyclic N-H insertion product **6**, the cyclized azole **7** (a regioisomer of **3**) was observed as a minor product in the Ir-catalyzed reaction.




Intrigued by the facile cyclization to **7** in the absence of a dehydrating agent, we wondered if the selectivity of the Ir-catalyzed reaction could be inverted to favor formation of **7** directly from **4** and **5**. We describe herein a general method for the regioselective synthesis of 7- and 8-substituted-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazines from Ir-catalyzed reactions of 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine and β -keto sulfoxonium ylides. The nature of the ligand on Ir was found to significantly impact the selectivity of the reaction. In addition to imidazo-fused pyrrolopyrazines, a variety of azoles derived from other aryl amidines could also be easily accessed in high yields and selectivity.

Results and Discussions


Amine **4** reacted with sulfoxonium ylide **8** in the presence of catalytic [Ir(COD)Cl]₂ (COD = 1,5-cyclooctadiene) to form **9b** in 42% yield along with 10% of **9a** (Table 1, entry 1).² Significant amounts of the unreacted starting materials **4** and **8** remained after 24 h at 80 °C; no further conversion was observed by allowing the reaction to proceed for a longer time. A slightly improved yield of **9b** was observed upon addition of 4 Å molecular sieves to the reaction mixture (entry 2). A cationic Ir-complex generated *in situ* by addition of sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate (NaBARF₂₄) formed an inferior catalyst and afforded **9b** in only 17% yield (entry 3). We speculated that the moderate yield of **9b** was due to the inhibition of the Ir-catalyst by the reaction by-product, DMSO.³¹ In addition, **4**, **9a** and **9b** could bind to Ir and inhibit reaction.²

Table 1: Evaluation of reaction parameters for Ir-catalyzed N-H insertion reaction to favor formation of azole **9a**



Entry	L	Solvent	Additive ^a	9a (%)	9b (%)	9a/9b
1	none	DCE	none	10	42	0.24
2	none	DCE	4 Å MS	9	57	0.16
3	none	DCE	4 Å MS, NaBARF ₂₄	5	17	0.29
4	I	DCE	none	11	16	0.69
5	I	DCE	NaBARF ₂₄	57	4	14
6	I	DCE	4 Å MS, NaBARF ₂₄	60	5	12
7	II	DCE	4 Å MS, NaBARF ₂₄	26	4	6.5
8	III	DCE	4 Å MS, NaBARF ₂₄	52	6	8.7
9	I	DCE	4 Å MS, NaOTf	67	6	11
10 ^b	I	DCE	4 Å MS, NaOTf	81	5	16

All experiments were conducted with **4** (1.5 equiv), **8** (1 equiv), [Ir(COD)Cl]₂ (2.5 mol%), L (5 mol%), 4 Å MS (240 wt% with respect to ylide) in DCE (0.25 M) at 80 °C unless stated otherwise. The yield and ratio of **9a** and **9b** were determined by HPLC analysis of the reaction mixture at 210 nm.. (a) 5 mol%. (b) **4** (1.0 equiv) and **8** (1.5 equiv) were used.




Our approach to improving the yield of **9b** was to overcome the suspected catalytic inhibition by introducing a ligand onto Ir that would form a more robust catalyst. The use of 1,10-phenanthroline (**I**) formed **9b** in a disappointing yield; however, **9a** was formed in a noticeably higher ratio (compare entries 1 and 4). To our surprise, the addition of sub-stoichiometric amounts of NaBARF₂₄ to a mixture of [Ir(COD)Cl]₂ and **I** formed a catalyst system that inverted the selectivity of the reaction and favored formation of the cyclized product **9a** over **9b** in 14:1 ratio (entry 5) providing **9a** in a synthetically useful yield. The beneficial effect of the tetra-arylborate counteranion on the overall yield of the reaction is in contrast to the much lower yield observed when NaBARF₂₄ was used with [Ir(COD)Cl]₂ in the absence of added ligand. As observed earlier, addition of molecular sieves to the reaction led to a slightly improved yield (entry 6). 4,7-Dimethoxy-1,10-phenanthroline (**II**) and 4,4'-*tert*-butylpyridine (**III**) also favored **9a** as the major product but were inferior to **I** (entries 7 and 8). Other nitrogen containing ligands and triphenylphosphine formed **9b** as the major product,³² clearly indicating that the nature of ligand on Ir impacts both the selectivity and yield of the reaction. Of the non-

coordinating counteranion additives explored the highest yield of **9a** was observed in the presence of NaOTf (entry 9), and further improvement in the yield was observed by using 1.5 equivalents of the sulfoxonium ylide **8** (entry 10).³³ No product formation was observed in the absence of $[\text{Ir}(\text{COD})\text{Cl}]_2$.

Having established optimal reaction conditions to selectively form **9a**, the scope of the sulfoxonium ylide was explored. Reactions of ylides containing either alkyl (Table 2, entries 1 and 2) or electron-poor aryl groups (Table 2, entries 3 and 4) connected to the carbonyl formed azoles in higher selectivity than reactions of sulfoxonium ylides containing electron-rich aryl groups (entries 8 and 9) connected to the carbonyl. Bromo, ester, nitro, *N,N*-dimethylamino, ether and thiophene functionalities were all well-tolerated under the reaction conditions providing azoles in synthetically useful yields. Moderate to good selectivity for the formation of **9-19a** over **9-19b** was observed utilizing a wide range of sterically and electronically varied β -keto sulfoxonium ylides. The selectivity could be reversed to favor β -keto amine products by conducting the Ir-catalyzed N-H insertion reaction in the absence of **I** and NaOTf (Condition B). Under these conditions, β -keto amines **9b**, **12b**, **14b** and **18b** were prepared with high selectivity over the corresponding cyclic products **9a**, **12a**, **14a**, and **18a**.

Table 2: Substrate scope of Ir-catalyzed reaction of 2-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (**4**) with β -keto sulfoxonium ylides




entry	R =	Condition	yield ^a	ratio of products ^b
1		A B	65 42	9a/9b = 16:1 = 1:4
2		A	66	10a/10b = 16:1
3		A	37	11a/11b = NA ^c
4		A B	49 37	12a/12b = NA ^c = 1:19
5		A	64	13a/13b = 5:1









6		A B	60 31	14a/14b = 7:1 = 1:31
7		A	60	15a/15b = 5:1
8		A	49	16a/16b = 3:1
9		A	49	17a/17b = 4:1
10		A B	63 33	18a/18b = 4:1 = 1:48
11		A	41	19a/19b = 4:1

All experiments were run with **4** (1 equiv) and ylide (1.5 equiv). (a) Isolated yield. (b) Ratio was determined by ^1H NMR spectroscopy. (c) The β -keto amine was not detected in the ^1H NMR spectra of the crude reaction mixture.

The scope of other aryl amidines (**21-24**) that could engage with ylide **20** was also explored (Table 3). Good to excellent selectivity for **25a-28a** over **25b-28b** was observed providing rapid access to pharmaceutically relevant heterocyclic compounds in high yields. The selectivity for the formation of azole over β -keto amine depended on the nature of the aryl amidine. While azoles **26a** and **28a** were the only products observed in the reactions of quinolin-2-amine and pyrimidin-2-amine (entries 2 and 4), **25a** and **27a** were favored over **25b** and **27b** in 24:1 and 11:1 ratios respectively (entries 1 and 3).

Table 3: Substrate scope of Ir-catalyzed reaction of **20** with aryl amidines




entry	amidine	desired product	yield ^a	ratio of products ^b
1			92	25a/25b = 24:1
2			66	26a/26b = NA ^c
3			69	27a/27b = 11:1
4			68	28a/28b = NA ^c

All reactions were run with [Ir(COD)Cl]₂ (2.5 mol%), **I** (5 mol%), NaOTf (5 mol%), 4 Å MS (240 wt%), amidine (1 equiv), **20** (1 equiv), in 1,2-dichloroethane at 80 °C for 24 h. (a) Isolated yield. (b) Ratio was determined by ¹H NMR spectroscopy. (c) The acyclic product (β-keto amine) was not detected in the ¹H NMR spectra of the crude reaction mixture.

The underlying reasons for the influence of ligand and counteranion on the selectivity of Ir-catalyzed reactions of β-keto sulfoxonium ylides with **4** is not immediately obvious. As discussed above, while β-keto amines are the preferred product in the presence of [(COD)IrCl]₂, azoles are the preferred product in the presence of [(COD)IrCl]₂, **I**, and NaOTf. No conversion of the β-keto amines **9b** to azoles **9a** was observed when isolated **9b** was heated for 24 h at 80 °C in the presence of [(COD)IrCl]₂, **I**, and NaOTf, suggesting that **9b** and **9a** were formed via divergent pathways. The mechanism of generation of Ir-carbene intermediates from sulfoxonium ylides and the subsequent reaction of the carbene intermediate with amines have not been studied in detail.^{34,35} We propose that **4** acts as a supporting ligand for Ir in the absence of added ligand to form the four-coordinate intermediate **A** (Figure 1, left). The Ir-amine complex **A** reacts with sulfoxonium ylide to form the Ir-carbene intermediate **B**, and intramolecular reaction of amine with Ir-carbenoid forms **C**. Protonation of Ir-enolate forms Ir complex **D**, which undergoes ligand exchange to release the product and reform complex **A**. In contrast, when 1,10-phenanthroline is introduced as a ligand in the presence of NaOTf, formation of the four-coordinate Ir-complex **E** from the reaction of [(COD)IrCl]₂ with 1,10-phenanthroline and NaOTf likely occurs before coordination of the amine substrate **4** to the metal (Figure 1, right). Complex **E** reacts with sulfoxonium ylide to form the Ir-carbene intermediate **F**. Intermolecular reaction of **4** with **F** generates intermediate **G**, which tautomerizes to form intermediate **H**.

Protonation of Ir-enolate reforms complex **E** and generates imine **J** that cyclizes to form azole **9a**.


Figure 1. Proposed mechanisms for the formation of β -keto amine (left) or azole (right)



The hypothesis proposed in Figure 1 was supported by following the interaction of $[(\text{COD})\text{IrCl}]_2$ with **4** and 1,10-phenanthroline by ^1H - ^{15}N HMBC NMR spectroscopy (Figure 2). Consistent with literature reports,³⁶ ^{15}N signals for **b** and **c** were observed at -86 and -119.8 ppm, while **d** was observed at -207.9 ppm. The ^{15}N signal for **a** is expected between -300 to -330 ppm but was not observed. The broad ^1H signal observed for the $-\text{NH}_2$ protons most likely causes the absence of ^{15}N signal for **a** in the ^1H - ^{15}N HMBC NMR spectrum. When **4** and 0.5 equivalent of $[(\text{COD})\text{IrCl}]_2$ were mixed in CD_2Cl_2 , the ^{15}N signal for **b** shifted to -176.6 ppm from -119.8 ppm. A clear signal for **a** was now observed at -308.0 ppm, and minimal change in the signals for **c** and **d** was observed. The significant chemical shift in the ^{15}N NMR peak for **b** is strong, albeit indirect, evidence for interaction of **4** with $[(\text{COD})\text{IrCl}]_2$. In a similar experiment, the ^{15}N NMR signal for the nitrogen atoms in 1,10-phenanthroline (**e**) shifted from -72.9 ppm in the *absence* of $[(\text{COD})\text{IrCl}]_2$ to -134.9 ppm in the *presence* of 0.5 equivalent of $[(\text{COD})\text{IrCl}]_2$ in CD_2Cl_2 (Figure 3b). When 1 equivalent each of **4** and 1,10-phenanthroline and 0.5 equivalent of $[(\text{COD})\text{IrCl}]_2$ were mixed together in CD_2Cl_2 , the ^{15}N NMR signal for **e** was observed at -134.9 ppm, whereas the ^{15}N NMR signal for **b** was similar to that observed in the absence of $[(\text{COD})\text{IrCl}]_2$.³⁷ These


set of ^1H - ^{15}N HMBC NMR data suggest that 1,10-phenanthroline is a better ligand for Ir than **4**. This observation is consistent with our proposal of formation of the Ir-complex **E** in the presence of 1,10-phenanthroline before **4** interacts with the metal (Figure 1). As proposed in Figure 1, the point of interaction of **4** with Ir determines the nature of the product formed in the reaction.

Figure 2. Interaction of $[(\text{COD})\text{IrCl}]_2$ with amine (**4**) and 1,10-phenanthroline as studied by ^1H - ^{15}N HMBC spectroscopy.




Further insight into the reaction mechanism was obtained by following the reactions by mass and ^1H NMR spectroscopy. Although no direct evidence for the generation of Ir-carbene intermediate **B** was obtained by ^1H NMR spectroscopy, formation of DMSO was observed in the reaction of **4** with **8** catalyzed by $[(\text{COD})\text{IrCl}]_2$.³⁸ The insertion of Ir into **4** was determined to be reversible based on mass spectral studies with $\text{DMSO-}^{13}\text{C}_2$ (Table S2). When stoichiometric amounts of **4**, **8**, and $[(\text{COD})\text{IrCl}]_2$ were reacted in DCE-d_4 at 40 °C, the rate of DMSO formation matched the rate of formation of **9b** (Figure 3). This suggests that the formation of Ir-carbene intermediate **B** is the slow step of the reaction (Figure 1, left).³⁹ Fast, intramolecular reaction of the amine with Ir-carbene followed by protodemetalation likely generates the β -keto amine **9b**.

Figure 3. Formation of DMSO and **9b** in a stoichiometric reaction of **4**, and **8** with $[\text{Ir}(\text{COD})\text{Cl}]_2$



No evidence for the generation of Ir-carbene intermediate **F** was obtained by ^1H NMR spectroscopy during the reaction of **4** with **8** catalyzed by $[(\text{COD})\text{IrCl}]_2$, 1,10-phenanthroline and NaOTf. The rate of formation of DMSO was found to be similar to the rate of formation of azole **9a** when a reaction of **4** (1 equiv), **8** (10 equiv), $[(\text{COD})\text{IrCl}]_2$ (0.5 equiv), 1,10-phenanthroline (1 equivalent) and NaOTf (1 equiv) in DCE- d_4 was monitored by ^1H NMR spectroscopy at 80°C (Figure 4), suggesting that the generation of Ir-carbene intermediate **F** is the rate-limiting step for azole formation. The reaction of **4** with $[(\text{COD})\text{IrCl}]_2$ in the presence of 1,10-phenanthroline was also found to be reversible (Table S2).

Figure 4. Formation of DMSO and **9a** in a stoichiometric reaction of **4** and **8** with $[\text{Ir}(\text{COD})\text{Cl}]_2$, 1,10-phenanthroline and NaOTf



Although formation of both β -keto amine **9b** and azole **9a** proceed via reversible, rate-limiting generation of putative Ir-carbene intermediates, the preference for formation of **9a** or **9b** from Ir-catalyzed reactions of **4** with **8** is controlled by the nature of ligand. Insertion of the reaction by-product, DMSO, into the Ir-carbene intermediate likely inhibits the reaction. Our

future efforts will focus on studying the reactivity of sulfoxonium ylides containing leaving groups other than DMSO (such as diaryl sulfoxide) that will be capable of irreversibly generating the metal-carbene intermediate. We expect that identification of appropriate sulfoxonium ylide will further expand the efficiency and utility of the reported methodology.

Conclusions

In summary, a novel method for the synthesis of a variety of azoles from Ir-catalyzed reactions of β -ketosulfoxonium ylides with aryl amidines has been developed. This method uses bench stable sulfoxonium ylide precursors in place of diazo compounds, making preparation more practical and scalable. Two distinct products, β -keto amines or azoles can form from the Ir-catalyzed reactions of β -ketosulfoxonium ylides with aryl amidines. Azole is formed in preference to β -keto amine when 1,10-phenanthroline is used as the ligand for $[\text{Ir}(\text{COD})\text{Cl}]_2$ in conjunction with a non-coordinating anion, such as triflate. β -Keto amine is the preferred product in the absence of any additional ligand or counteranion for $[\text{Ir}(\text{COD})\text{Cl}]_2$. Mechanistic insight was provided based on NMR and mass spectral studies.

Experimental

General Information


All glassware was either oven-dried overnight at 130 °C or flame-dried under a stream of dry nitrogen prior to use. Unless otherwise specified, reagents were used as obtained from the vendor without further purification. Tetrahydrofuran and diethyl ether were freshly distilled from purple Na/benzophenone ketyl. Dichloromethane, acetonitrile and toluene were dried over CaH_2 and freshly distilled prior to use. All other solvents were purified in accordance with "Purification of Laboratory Chemicals".⁴⁰ Air- and moisture- sensitive reactions were performed using standard Schlenk techniques under an atmosphere of nitrogen. Analytical thin layer chromatography (TLC) was performed utilizing pre-coated silica gel 60 F₂₅₄ plates containing a fluorescent indicator, while preparative chromatography was performed using SilicaFlash P60

silica gel (230-400 mesh) via Still's method.⁴¹ Unless otherwise stated, the mobile phases for column chromatography were mixtures of dichloromethane/ethyl acetate. Columns were typically run using a gradient method, beginning with 100% dichloromethane and gradually increasing the polarity using ethyl acetate. Various stains were used to visualize reaction products, including *p*-anisaldehyde, KMnO₄, ceric ammonium molybdate (CAM stain) and iodine powder.

Routine NMR experiments were recorded in CDCl₃ at room temperature. Chemical shifts are reported in parts-per-million (ppm) relative to TMS (δ 0.00 ppm) for ¹H, and to the solvent signal (δ 77.0 ppm) for ¹³C. Scalar coupling constants are reported in hertz (Hz). Conventional 2D NMR experiments (COSY, HSQC, and HMBC) were recorded using standard pulse programs. In those cases where severe resonance overlap occurred, proton assignments were obtained by means of computer-assisted ¹H iterative full spin analysis (HiFSA).⁴² High-pressure liquid chromatography (HPLC) analyses were performed at 210 nm. Accurate mass measurements were acquired using electrospray ionization, time-of-flight analyzer or electron impact methods.


General procedure for synthesis of sulfoxonium ylides:

A 250 mL round-bottom flask equipped with a magnetic stir bar and reflux condenser was charged with 9.9 g (45 mmol) trimethylsulfoxonium iodide and 150 mL THF under nitrogen. NaO^tBu (4.5 g, 47.25 mmol) was added, heated to reflux and allowed to stir for 2 h. After 2 h, the reaction mixture was cooled to the room temperature, followed by dropwise addition of ester or acid chloride (15 mmol). The reaction mixture was stirred for 18 h, then quenched with 250 mL water. The layers were separate and the aqueous layer was extracted with 3 x 150 mL EtOAc, washed with 150 mL saturated NaCl solution, stirred over Na₂SO₄, filtered, then filtrate concentrated *in vacuo*. The resulting solid was charged to a 50 mL round-bottom flask, 16 mL EtOAc was added. Reaction was heated to 50 °C for 1 h, then allowed to cool to room temperature with constant stirring. The resulting slurry was filtered through Buchner funnel under vacuum, the solid was washed with ice-cold EtOAc to yield pure product, which was dried under vacuum for 12 h to remove residual solvents.


1-(Dimethyl(oxo)-λ⁶-sulfanylidene)-3-phenoxypropan-2-one

Following the general procedure methyl phenoxyacetate (2.53 g, 15 mmol) was converted to the 1-(Dimethyl(oxo)-λ⁶-sulfanylidene)-3-phenoxypropan-2-one (1.86 g, 55%). The product was isolated as crystalline, white solid.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 7.29 (m, 2H), 6.97 (m, 1H), 6.92 (m, 2H), 4.91 (s, 1H), 4.41 (s, 2H), 3.44 (s, 6H). ¹³C NMR (176 MHz, CDCl₃), δ: 185.7, 158.2, 129.5, 121.2, 114.6, 71.2, 68.9, 42.2. HRMS (ESI) *m/z* calculated for C₁₁H₁₄O₃S [M + H]⁺ 227.0737, found 227.0737. mp 118-120 °C.

1-(Dimethyl(oxo)-λ⁶-sulfanylidene)-3-methylbutan-2-one


Following the general procedure isobutyryl chloride (1.60 g, 15 mmol) was converted to 1-(Dimethyl(oxo)-λ⁶-sulfanylidene)-3-methylbutan-2-one (290 mg, 12%). The product was isolated as acrystalline white solid. ¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 4.36 (s, 1H), 3.39 (s, 6H), 2.35 (hept, *J* = 6.9 Hz, 1H), 1.09 (d, *J* = 7.0 Hz, 6H). ¹³C NMR (176 MHz, CDCl₃), δ: 195.6, 67.0, 42.3, 38.8, 19.9. HRMS (ESI) *m/z* calculated for C₇H₁₄O₂S [M + H]⁺ 163.0788, found 163.0789. mp 135-137 °C.

2-(Dimethyl(oxo)-λ⁶-sulfanylidene)-1-(4-nitrophenyl)ethan-1-one

Following the general procedure 4-nitrobenzoyl chloride (2.78 g, 15 mmol) was converted to 2-(dimethyl(oxo)-λ⁶-sulfanylidene)-1-(4-nitrophenyl)ethan-1-one (1.95 g, 54%). The product was isolated as a crystalline yellow solid. ¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.24 (m, 2H), 7.93 (m, 2H), 5.03 (s, 1H), 3.55 (s, 6H). ¹³C NMR (176 MHz, CDCl₃), δ: 179.3, 149.1, 144.5, 127.5, 123.5, 70.2, 42.3. HRMS (ESI) *m/z* calculated for C₁₀H₁₁NO₄S [M + H]⁺ 242.0482, found 242.0477. mp 175-178 °C


Methyl-4-(2-dimethyl(oxo)- λ^6 -sulfanylidene)-acetylbenzoate

Following the general procedure, methyl 4-(chlorocarbonyl)benzoate (2.98 g, 15 mmol) was converted to methyl-4-(2-dimethyl(oxo)- λ^6 -sulfanylidene)-acetylbenzoate (1.03 g, 27%). The product was isolated as a crystalline yellow solid. ^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 8.06 (m, 2H), 7.85 (m, 2H), 5.02 (s, 1H), 3.93 (s, 3H), 3.53 (s, 6H). ^{13}C NMR (176 MHz, CDCl_3), : 181.0, 166.7, 142.8, 131.8, 129.5, 126.5, 69.3, 52.2, 42.4. HRMS (ESI) m/z calculated for $\text{C}_{12}\text{H}_{14}\text{O}_4\text{S}$ $[\text{M} + \text{H}]^+$ 255.0686, found 255.0685. mp 158-160 °C.

1-(4-Bromophenyl)-2-(2-dimethyl(oxo)- λ^6 -sulfanylidene)ethan-1-one


Following the general procedure, 4-bromobenzoyl chloride (3.29 g, 15 mmol) was converted to 1-(4-Bromophenyl)-2-(2-dimethyl(oxo)- λ^6 -sulfanylidene)ethan-1-one (3.75 g, 86%). The product was isolated as a crystalline yellow solid.

^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 7.66 (m, 2H), 7.52 (m, 2H), 4.94 (s, 1H), 3.51 (s, 6H). ^{13}C NMR (176 MHz, CDCl_3), δ : 180.9, 137.7, 131.3, 128.2, 125.2, 68.4, 42.5. HRMS (ESI) m/z calculated for $\text{C}_{10}\text{H}_{11}\text{BrO}_2\text{S}$ $[\text{M} + \text{H}]^+$ 274.9736, found 274.9735. mp 149-150 °C.

2-(Dimethyl(oxo)- λ^6 -sulfanylidene)-1-phenylethan-1-one


Following the general procedure, benzoyl chloride (2.11 g, 15 mmol) was converted to 2-(Dimethyl(oxo)- λ^6 -sulfanylidene)-1-phenylethan-1-one (1.32 g, 34%). The product was isolated

as a crystalline white solid. ^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 7.80 (m, 2H), 7.43 (m, 1H), 7.39 (m, 2H), 4.98 (s, 1H), 3.52 (s, 6H). ^{13}C NMR (176 MHz, CDCl_3), δ : 182.3, 138.8, 130.7, 128.1, 126.5, 68.1, 42.5. HRMS (ESI) m/z calculated for $\text{C}_{10}\text{H}_{12}\text{O}_2\text{S}$ $[\text{M} + \text{H}]^+$ 197.0631, found 197.0626. mp 114-116 $^\circ\text{C}$.




1-(4-(tert-butyl)phenyl)-2-(dimethyl(oxo)- λ^6 -sulfanylidene)ethan-1-one

Following the general procedure, 4-*tert*-butylbenzoyl chloride (2.95 g, 15 mmol) was converted to 1-(4-(tert-butyl)phenyl)-2-(dimethyl(oxo)- λ^6 -sulfanylidene)ethan-1-one (2.81 g, 74%). The product was isolated as a crystalline tan solid. ^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 7.74 (m, 2H), 7.41 (m, 2H), 4.95 (s, 1H), 3.51 (s, 6H), 1.33 (s, 9H). ^{13}C NMR (176 MHz, CDCl_3), δ : 182.2, 154.1, 136.1, 126.3, 125.1, 67.6, 42.6, 34.8, 31.2. HRMS (ESI) m/z calculated for $\text{C}_{14}\text{H}_{20}\text{O}_2\text{S}$ $[\text{M} + \text{H}]^+$ 253.1257, found 253.1259. mp 168-170 $^\circ\text{C}$.




1-(3,4-Dimethoxyphenyl)-2-(dimethyl(oxo)- λ^6 -sulfanylidene)ethan-1-one

Following the general procedure, methyl 3,4-dimethoxybenzoate (2.94 g, 15 mmol) was converted to 1-(3,4-Dimethoxyphenyl)-2-(dimethyl(oxo)- λ^6 -sulfanylidene)ethan-1-one (696 mg, 18%). The product was isolated as a crystalline light yellow solid. ^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 7.44 (d, J = 2.0 Hz), 7.36 (dd, J = 8.3, 2.0 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 4.92 (s, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.51 (s, 6H). ^{13}C NMR (176 MHz, CDCl_3) δ : 181.7, 151.2, 148.6, 131.8, 119.8, 110.1, 109.3, 67.2, 55.9, 55.9, 42.7. HRMS (ESI) m/z calculated for $\text{C}_{12}\text{H}_{16}\text{O}_4\text{S}$ $[\text{M} + \text{H}]^+$ 257.0843, found 257.0844. mp 131-133 $^\circ\text{C}$.


2-(Dimethyl(oxo)- λ^6 -sulfanylidene)-1-(4-(dimethylamino)phenyl)ethan-1-one

Following the general procedure, 4-(dimethylamino)benzoyl chloride (2.75 g, 15 mmol) was converted to 2-(Dimethyl(oxo)- λ^6 -sulfanylidene)-1-(4-(dimethylamino)phenyl)ethan-1-one (1.52 g, 42%). The product was isolated as a crystalline yellow solid. ^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 7.77 (m, 2H), 6.72 (m, 2H), 4.91 (s, 1H), 3.56 (s, 6H), 3.07 (s, 6H). ^{13}C NMR (176 MHz, CDCl_3) δ : 182.3, 152.2, 128.0, 126.5, 110.9, 65.7, 42.9, 40.2. HRMS (ESI) m/z calculated for $\text{C}_{12}\text{H}_{17}\text{NO}_2\text{S}$ $[\text{M} + \text{H}]^+$ 240.1053, found 240.1051. mp 166-168 °C.

2-(Dimethyl(oxo)- λ^6 -sulfanylidene)-1-(*o*-tolyl)ethan-1-one

Following the general procedure, *o*-toluoyl chloride (2.30 g, 15 mmol) was converted to 2-(Dimethyl(oxo)- λ^6 -sulfanylidene)-1-(*o*-tolyl)ethan-1-one (1.08 g, 34%). The product was isolated as a crystalline white solid.

^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 7.41 (m, 1H), 7.24 (m, 1H), 7.18 (m, 1H), 7.15 (m, 1H), 4.64 (s, 1H), 3.52 (s, 6H), 2.47 (s, 3H). ^{13}C NMR (176 MHz, CDCl_3), δ : 186.8, 140.9, 135.5, 130.8, 128.9, 127.2, 125.3, 71.0, 42.3, 20.1. HRMS (ESI) m/z calculated for $\text{C}_{11}\text{H}_{14}\text{O}_2\text{S}$ $[\text{M} + \text{H}]^+$ 211.0788, found 211.0787. mp 104-106 °C.

2-(Dimethyl(oxo)- λ^6 -sulfanylidene)-1-(thiophen-2-yl)ethan-1-one


Following the general procedure, methyl 2-thiophene carboxylate (2.13 g, 15 mmol) was converted to 2-(Dimethyl(oxo)- λ^6 -sulfanylidene)-1-(thiophen-2-yl)ethan-1-one (1.64 g, 54%). The product was isolated as a crystalline tan solid.

^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 7.44 (dd, J = 3.7, 1.2 Hz, 1H), 7.41 (dd, J = 5.0, 1.2 Hz, 1H), 7.04 (dd, J = 5.0, 3.7 Hz, 1H), 4.88 (s, 1H), 3.51 (s, 6H). ^{13}C NMR (176 MHz,

CDCl₃) δ : 175.6, 145.6, 129.0, 127.5, 127.0, 67.0, 42.8. HRMS (ESI) m/z calculated for C₈H₁₀O₂S₂ [M + H]⁺ 203.0195, found 203.0191. mp 165-167 °C.

General procedure for Ir-catalyzed N-H insertion reaction


To a thick-walled pressure tube in an inert atmosphere glove box was added ylide (1.72 mmol, 1.5 equiv) and amine (1.15 mmol, 1 equiv), followed by [Ir(COD)Cl]₂ (0.029 mmol, 0.025 equiv), 1,10-phenanthroline (0.058 mmol, 0.05 equiv), NaOTf (0.058 mmol, 0.05 equiv), and powdered 4 Å molecular sieves (1.15 g). 1,2-Dichloroethane (4.6 mL) was added, rinsing down the sides of the pressure tube, and reaction was capped and removed from the glove box. The reaction was heated to 80 °C for 24 h, then cooled to room temperature, vacuum filtered through medium fritted funnel, washed with CH₂Cl₂, and concentrated under reduced pressure. The resulting mixture was purified *via* column chromatography using CH₂Cl₂/EtOAc gradient unless otherwise specified.



7-(Phenoxymethyl)-3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine (**9a**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-amine (72 mg, 0.25 mmol) was converted to 7-(Phenoxymethyl)-3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine (72 mg, 68%). The resulting crystalline yellow solid was isolated after column chromatography using a 5 to 40% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃) δ (mult., J , nH): 8.81 (s, 1H), 8.08 (m, 2H), 7.86 (s, 1H), 7.73 (d, J = 4.0 Hz, 1H), 7.30 (m, 2H), 7.29 (m, 1H), 7.28 (m, 1H), 7.02 (m, 2H), 6.97 (m, 1H), 6.72 (d, J = 4.0 Hz, 1H), 5.35 (s, 2H), 2.38 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ 158.3, 145.8, 145.6, 139.4, 136.6, 134.9, 132.9, 129.9, 129.5, 128.2, 123.8, 121.3, 118.4, 114.7, 109.8, 98.4, 64.9, 21.7. HRMS (ESI) m/z calculated for C₂₂H₁₈N₄O₃S [M + H]⁺ 419.1173, found 419.1165. mp 153-155 °C.



1-Phenoxy-3-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)propan-2-one (**9b**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25mmol) was converted to 1-Phenoxy-3-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)propan-2-one (11 mg, 10%). The resulting amorphous orange solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 7.98 (m, 2H), 7.80 (s, 1H), 7.75 (d, *J* = 4.0 Hz, 1H), 7.33 (m, 2H), 7.25 (m, 2H), 7.02 (m, 1H), 6.94 (m, 2H), 6.54 (d, *J* = 4.0 Hz, 1H), 5.29 (t, *J* = 4.9 Hz, 1H), 4.73 (s, 2H), 4.55 (d, *J* = 4.9 Hz, 2H), 2.37 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ: 204.1, 157.5, 151.8, 145.3, 138.6, 135.3, 135.0, 129.8, 128.7, 128.2, 127.7, 122.0, 114.5, 105.8, 72.0, 49.1, 21.6. HRMS (ESI) *m/z* calculated for C₂₂H₂₀N₄O₄S [M + H]⁺ 437.1279, found 437.1277.




7-Isopropyl-3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (**10a**):

Following the general procedure 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 7-Isopropyl-3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (270 mg, 66%). The resulting crystalline white solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.77 (s, 1H), 8.06 (m, 2H), 7.70 (d, *J* = 4.0 Hz, 1H), 7.57 (s, 1H), 7.28 (m, 2H), 6.71 (d, *J* = 4.0 Hz, 1H), 3.18 (hept, *J* = 6.9 Hz, 1H), 2.37 (s, 3H), 1.39 (d, *J* = 7.0 Hz, 6H). ¹³C NMR (176 MHz, CDCl₃), δ 156.5, 145.9, 139.3, 136.2, 134.9,


132.9, 129.8, 128.0, 123.5, 118.3, 107.2, 98.4, 28.7, 22.5, 21.6. HRMS (ESI) m/z calculated for $C_{18}H_{18}N_4O_2S$ $[M + H]^+$ 355.1224, found 355.1224. mp 197-199 °C.



3-Methyl-1-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)butan-2-one (**10b**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 3-Methyl-1-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)butan-2-one (24 mg, 6%). The resulting crystalline white solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH_2Cl_2 .

1H NMR (700 MHz, $CDCl_3$), δ (mult., J , nH): 7.97 (m, 2H), 7.78 (s, 1H), 7.74 (d, J = 4.0 Hz, 1H), 7.26 (m, 2H), 6.54 (d, J = 4.0 Hz, 1H), 5.40 (t, J = 4.3 Hz, 1H), 4.32 (d, J = 4.2 Hz, 2H), 2.74 (hept, J = 6.9 Hz, 1H), 2.37 (s, 3H), 1.19 (d, J = 6.9 Hz, 7H). ^{13}C NMR (176 MHz, $CDCl_3$), δ : 210.0, 151.9, 145.2, 138.6, 135.3, 134.8, 129.7, 128.5, 128.4, 127.7, 105.8, 49.3, 39.0, 21.6, 18.3. HRMS (ESI) m/z calculated for $C_{18}H_{20}N_4O_3S$ $[M + H]^+$ 373.1251, found 373.1255. mp 134-137 °C.




7-(4-Nitrophenyl)-3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (**11a**):

Following the general procedure 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 7-(4-Nitrophenyl)-3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine

(148 mg, 34%). The resulting crystalline orange solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.87 (s, 1H), 8.33 (m, 2H), 8.19 (s, 1H), 8.16 (m, 2H), 8.11 (m, 2H), 7.78 (d, *J* = 4.0 Hz, 1H), 7.33 (m, 2H), 6.79 (d, *J* = 3.9 Hz, 1H), 2.39 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ: 147.7, 146.0, 145.2, 140.2, 139.2, 137.0, 134.8, 133.1, 129.9, 128.3, 126.8, 124.3, 124.1, 118.2, 108.8, 98.2, 21.7. HRMS (ESI) *m/z* calculated for C₂₁H₁₅N₅O₄S [M + H]⁺ 434.0918, found 434.0919. mp 250 °C (decomp).



1-(4-Nitrophenyl)-2-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (**11b**):

Following the general procedure 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 1-(4-Nitrophenyl)-2-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (126 mg, 28%). The resulting crystalline yellow solid was isolated in after column chromatography using a 2→10% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.37 (m, 2H), 8.23 (m, 2H), 7.99 (m, 2H), 7.88 (s, 1H), 7.77 (d, *J* = 3.9 Hz, 1H), 7.28 (d, m, 2H), 6.56 (d, *J* = 4.0 Hz, 1H), 5.60 (t, *J* = 4.3 Hz, 1H), 4.95 (d, *J* = 4.3 Hz, 2H), 2.38 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ: 194.0, 151.6, 150.8, 145.3, 139.1, 138.5, 135.3, 135.0, 129.8, 129.1, 128.7, 128.4, 127.8, 124.1, 105.7, 48.8, 21.6. HRMS (ESI) *m/z* calculated for C₂₁H₁₇N₅O₅S [M + H]⁺ 452.1024, found 452.1026. mp 195-197 °C.



Methyl 4-(3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine-7-yl)benzoate (**12a**):

Following the general procedure, 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to Methyl 4-(3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine-7-yl)benzoate (250 mg, 48%). The resulting crystalline orange solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.86 (s, 1H), 8.15 (s, 1H), 8.13 (m, 2H), 8.10 (m, 2H), 8.06 (m, 2H), 7.76 (d, *J* = 4.0 Hz, 1H), 7.32 (m, 2H), 6.78 (d, *J* = 4.0 Hz, 1H), 3.94 (s, 3H), 2.39 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ: 166.7, 146.5, 145.9, 140.1, 137.2, 136.8, 134.8, 133.0, 130.2, 129.9, 129.9, 128.2, 126.1, 123.9, 118.2, 108.3, 98.4, 52.2, 21.7. HRMS (ESI) *m/z* calculated for C₂₃H₁₈N₄O₄S [M + H]⁺ 447.1122, found 447.1123. mp 263 °C (decomp).



Methyl 4-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazin-2-yl)glycyl)benzoate (**12b**):

Following the general procedure, 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to Methyl 4-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazin-2-yl)glycyl)benzoate (59 mg, 11%). The resulting crystalline yellow solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.17 (m, 2H), 8.11 (m, 2H), 7.98 (m, 2H), 7.87 (s, 1H), 7.75 (d, *J* = 4.0 Hz, 1H), 7.27 (m, 2H), 6.56 (d, *J* = 4.0 Hz, 1H), 5.68 (t, *J* = 4.4 Hz, 1H), 4.92 (d, *J* = 4.3 Hz, 2H), 3.97 (s, 3H), 2.37 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ: 194.8, 166.0, 151.8, 145.3, 138.6, 137.8, 135.3, 134.9, 134.7, 130.0, 129.7, 128.6, 128.5, 127.9, 127.76, 105.8, 52.6, 48.6, 21.6. HRMS (ESI) *m/z* calculated for C₂₃H₂₀N₄O₅S [M + H]⁺ 465.1228, found 465.1227. mp 200-203 °C.



7-(4-Bromophenyl)-3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (**13a**):

Following the general procedure 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25mmol) was converted to 7-(4-Bromophenyl)-3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (74 mg, 64%). The resulting crystalline orange solid was isolated after column chromatography using a 2→10% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.83 (s, 1H), 8.09 (m, 2H), 8.06 (s, 1H), 7.85 (m, 2H), 7.75 (d, *J* = 4.1 Hz, 1H), 7.59 (m, 2H), 7.33 (m, 2H), 6.77 (d, *J* = 4.1 Hz, 1H), 2.39 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ 146.7, 145.9, 140.0, 136.6, 134.9, 133.1, 132.0, 131.9, 129.9, 128.2, 127.8, 123.9, 122.7, 118.2, 107.5, 98.4, 21.7. HRMS (ESI) *m/z* calculated for C₂₁H₁₅N₄O₂SBr [M + H]⁺ 467.0172, found 467.0170. mp 245 °C (decomp).




1-(4-Bromophenyl)-2-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (**13b**):

Following the general procedure, 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25 mmol) was converted to 1-(4-Bromophenyl)-2-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (14 mg, 13%). The resulting crystalline yellow solid was isolated after column chromatography using a 2→10% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 7.98 (m, 2H), 7.92 (m, 2H), 7.86 (s, 1H), 7.75 (d, *J* = 4.0 Hz, 1H), 7.66 (m, 2H), 7.27 (m, 2H), 6.56 (d, *J* = 4.0 Hz, 1H), 5.66 (t, *J* = 4.3 Hz, 1H), 4.86 (d, *J* = 4.4 Hz, 2H), 2.37 (s, 3H). ¹³C NMR (176 MHz, CDCl₃): 194.2, 151.9, 145.3, 138.6,


135.3, 134.9, 133.3, 132.3, 129.8, 129.4, 129.3, 128.6, 128.5, 127.8, 105.8, 48.2, 21.6. HRMS (ESI) m/z calculated for $C_{21}H_{17}N_4O_3SBr$ $[M + H]^+$ 485.0278, found 485.0276. mp 212-214 °C.



7-Phenyl-3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (**14a**):

Following the general procedure, 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25 mmol) was converted to 7-Phenyl-3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (58 mg, 60%). The resulting crystalline off-white solid was isolated after column chromatography using a 1→10% gradient of EtOAc in CH_2Cl_2 .


1H NMR (700 MHz, $CDCl_3$), δ (mult., *J*, nH): 8.84 (s, 1H), 8.09 (m, 2H), 8.07 (s, 1H), 7.98 (m, 2H), 7.73 (d, *J* = 4.0, 1H), 7.45 (m, 2H), 7.37 (m, 1H), 7.31 (m, 2H), 6.77 (d, *J* = 4.0 Hz, 1H), 2.38 (s, 3H). ^{13}C NMR (176 MHz, $CDCl_3$): 147.9, 145.8, 139.9, 136.6, 134.9, 133.0, 132.9, 129.9, 128.9, 128.7, 128.1, 126.3, 123.7, 118.2, 107.4, 98.4, 21.7. HRMS (ESI) m/z calculated for $C_{21}H_{16}N_4O_2S$ $[M + H]^+$ 389.1067, found 389.1069. mp 233-235 °C



1-Phenyl-2-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (**14b**):

Following the general procedure, 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25 mmol) was converted to 1-Phenyl-2-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (9 mg, 9%). The resulting amorphous orange solid was isolated column chromatography using a 2→10% gradient of EtOAc in CH_2Cl_2 .


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.05 (m, 2H), 7.98 (m, 2H), 7.85 (s, 1H, H3), 7.74 (d, *J* = 4.0 Hz, 1H), 7.63 (m, 1H), 7.51 (m, 2H), 7.26 (m, 2H), 6.56 (d, *J* = 4.0 Hz, 1H), 5.73 (t, *J* = 4.4 Hz, 1H), 4.89 (d, *J* = 4.4 Hz, 2H), 2.37 (s, 3H). ¹³C NMR (176 MHz, CDCl₃): 195.0, 152.0, 145.2, 138.6, 135.3, 134.8, 134.6, 134.0, 129.7, 128.9, 128.6, 128.4, 127.9, 127.7, 105.8, 48.2, 21.6. HRMS (ESI) *m/z* calculated for C₂₁H₁₈N₄O₃S [M + H]⁺ 407.1173, found 407.1175.



7-(4-(*tert*-Butyl)phenyl)-3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (**15a**):

Following the general procedure, 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25 mmol) was converted to 7-(4-(*tert*-Butyl)phenyl)-3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (67 mg, 60%). The resulting crystalline orange solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.84 (s, 1H), 8.09 (m, 2H), 8.05 (s, 1H), 7.91 (m, 2H), 7.73 (d, *J* = 4.0 Hz, 1H), 7.49 (m, 2H), 7.30 (m, 2H), 6.77 (d, *J* = 4.0 Hz, 1H), 2.38 (s, 3H), 1.36 (s, 9H). ¹³C NMR (176 MHz, CDCl₃), δ 151.9, 148.0, 145.8, 139.9, 136.5, 134.9, 133.0, 130.1, 129.9, 128.1, 126.0, 125.8, 123.6, 118.2, 107.2, 98.5, 34.7, 31.3, 21.6. HRMS (ESI) *m/z* calculated for C₂₅H₂₄N₄O₂S [M + H]⁺ 445.1693, found 445.1692. mp 235 °C (decomp).



1-(4-(*tert*-Butyl)phenyl)-2-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (**15b**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25 mmol) was converted to 1-(4-(*tert*-Butyl)phenyl)-2-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (14 mg, 12%). The resulting crystalline brown solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*): 8.06 (m, 2H), 8.04 (m, 2H), 7.92 (s, 1H), 7.81 (d, *J* = 4.0 Hz, 1H), 7.59 (m, 2H), 7.33 (m, 2H), 6.64 (d, *J* = 4.0 Hz, 1H), 5.80 (t, *J* = 4.3 Hz, 1H), 4.93 (d, *J* = 4.3 Hz, 2H), 2.43 (s, 3H), 1.42 (s, 9H). ¹³C NMR (176 MHz, CDCl₃), δ 194.6, 158.1, 152.2, 145.3, 138.7, 135.4, 134.8, 132.1, 129.8, 128.7, 128.5, 128.0, 127.8, 125.9, 105.9, 48.4, 35.5, 31.3, 21.9. HRMS (ESI) *m/z* calculated for C₂₅H₂₆N₄O₃S [M + H]⁺ 463.1799, found 463.1797. mp 157-159 °C.



7-(3,4-Dimethoxyphenyl)-3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (**16a**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 7-(3,4-Dimethoxyphenyl)-3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (196 mg, 38%). The resulting crystalline orange solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.83 (s, 1H), 8.10 (m, 2H), 8.01 (s, 1H), 7.74 (d, *J* = 3.9 Hz, 1H), 7.59 (d, *J* = 2.0 Hz, 1H), 7.49 (dd, *J* = 8.3, 2.0 Hz, 1H), 7.34 – 7.29 (m, 2H), 6.95 (d, *J* = 8.4 Hz, 1H), 6.77 (d, *J* = 3.9 Hz, 1H), 4.01 (s, 3H), 3.94 (s, 3H), 2.39 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ 149.6, 149.4, 148.0, 145.8, 139.9, 136.3, 134.9, 133.1, 129.9, 128.2, 126.0, 123.7, 118.9, 118.2, 111.3, 109.4, 106.8, 98.4, 56.1, 56.0, 21.68. HRMS (ESI) *m/z* calculated for C₂₃H₂₀N₄O₄S [M + H]⁺ 449.1279, found 449.1277. mp 173-175 °C.



1-(3,4-Dimethoxyphenyl)-2-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (**16b**):


Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 1-(3,4-Dimethoxyphenyl)-2-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (102 mg, 19%). The resulting amorphous yellow solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 7.98 (m, 2H), 7.86 (s, 1H), 7.75 (d, *J* = 4.0 Hz, 1H), 7.71 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.57 (d, *J* = 2.0 Hz, 1H), 7.27 (m, 2H), 6.93 (d, *J* = 8.4 Hz, 1H), 6.57 (d, *J* = 4.0 Hz, 1H), 5.75 (t, *J* = 4.2 Hz, 1H), 4.85 (d, *J* = 4.2 Hz, 2H), 3.97 (s, 3H), 3.96 (s, 3H), 2.37 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ: 193.5, 154.0, 152.1, 149.3, 145.2, 138.6, 135.3, 134.8, 129.7, 128.7, 128.4, 127.8, 127.7, 122.6, 110.2, 110.0, 105.8, 56.1, 56.1, 47.7, 21.6. HRMS (ESI) *m/z* calculated for C₂₃H₂₂N₄O₅S [M + H]⁺ 467.1384, found 467.1387.

N,N-Dimethyl-4-(3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine-7-yl)aniline (**17a**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to *N,N*-Dimethyl-4-(3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine-7-yl)aniline (287 mg, 58%). The resulting crystalline yellow solid was isolated after column chromatography using a 5→30% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.80 (s, 1H), 8.08 (m, 2H), 7.94 (s, 1H), 7.86 (m, 2H), 7.71 (d, *J* = 4.0 Hz, 1H), 7.30 (m, 2H), 6.79 (m, 2H), 6.75 (d, *J* = 4.0 Hz, 1H), 3.02 (s, 6H), 2.38 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ 150.8, 148.7, 145.7, 139.9, 136.0, 135.0, 133.1, 129.8, 128.1, 127.3, 123.5, 120.9, 118.1, 112.3, 106.0, 98.5, 40.4, 21.7. HRMS (ESI) *m/z* calculated for C₂₃H₂₁N₅O₂S [M + H]⁺ 432.1489, found 432.1489. mp 229–231 °C.



1-(4-(Dimethylamino)phenyl)-2-((5-tosyl)-5H-pyrrolo[2,3-b]pyrazine-2-yl)amino)ethan-1-one
(**17b**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 1-(4-(Dimethylamino)phenyl)-2-((5-tosyl)-5H-pyrrolo[2,3-b]pyrazine-2-yl)amino)ethan-1-one (16 mg, 3%). The resulting crystalline orange solid was isolated after column chromatography using a 5→30% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 7.97 (m, 2H), 7.95 (m, 1H), 7.84 (s, 1H), 7.73 (d, *J* = 3.9 Hz, 2H), 7.26 (d, m, 2H), 6.68 (m, 2H), 6.57 (d, *J* = 4.0 Hz, 1H), 5.87 (t, *J* = 4.1 Hz, 1H), 4.77 (d, *J* = 4.1 Hz, 2H), 3.08 (s, 6H), 2.37 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ 192.3, 153.9, 152.3, 145.2, 138.7, 135.4, 134.6, 130.1, 129.7, 128.8, 128.2, 127.7, 122.3, 110.7, 105.9, 47.3, 40.0, 21.6. HRMS (ESI) *m/z* calculated for C₂₃H₂₃N₅O₃S [M + H]⁺ 450.1595, found 450.1604. mp 222 °C (decomp).




7-(*o*-Tolyl)-3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (**18a**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-b]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 7-(*o*-Tolyl)-3-tosyl-3H-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (282 mg, 61%). The resulting crystalline white solid was isolated after column chromatography using a 5→30% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.86 (s, 1H), 8.09 (m, 2H), 7.91 (s, 1H), 7.81 (m, 1H), 7.74 (d, *J* = 4.0 Hz, 1H), 7.31 (m, 2H), 7.297* (m, 1H), 7.293* (m, 1H), 7.292* (m, 1H), 6.78 (d, *J* = 4.0 Hz, 1H), 2.56 (s, 3H), 2.38 (s, 3H). *Indicates proton assignments obtained by ¹H


iterative full spin analysis. ^{13}C NMR (176 MHz, CDCl_3) δ : 147.7, 145.8, 139.1, 136.7, 135.9, 134.9, 132.9, 132.5, 131.0, 129.8, 129.8, 128.4, 128.1, 126.1, 123.6, 118.2, 109.9, 98.5, 21.7, 21.4. HRMS (ESI) m/z calculated for $\text{C}_{22}\text{H}_{18}\text{N}_4\text{O}_2\text{S}$ $[\text{M} + \text{H}]^+$ 403.1224, found 403.1232. mp 194-196 $^\circ\text{C}$.



1-(*o*-Tolyl)-2-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (**18b**):

Following the general procedure, 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (332 mg, 1.15 mmol) was converted to 1-(*o*-Tolyl)-2-((5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (58 mg, 12%). The resulting amorphous white solid was isolated after column chromatography using a 5 \rightarrow 30% gradient of EtOAc in CH_2Cl_2 .

^1H NMR (700 MHz, CDCl_3), δ (mult., J , nH): 7.98 (m, 2H), 7.85 (s, 1H), 7.83 (dd, J = 7.8, 1.3 Hz, 1H), 7.74 (d, J = 4.0 Hz, 1H), 7.45 (td, J = 7.5, 1.3 Hz, 1H), 7.32 (td, J = 7.8, 1.3 Hz, 1H), 7.30 (dd, J = 7.5, 1.3 Hz, 1H), 7.27 (m, 2H), 6.55 (d, J = 4.0 Hz, 1H), 5.69 (t, J = 4.5 Hz, 1H), 4.78 (d, J = 4.5 Hz, 2H), 2.56 (s, 3H), 2.37 (s, 3H). ^{13}C NMR (176 MHz, CDCl_3), δ : 198.1, 152.0, 145.2, 139.3, 138.6, 135.3, 134.8, 134.6, 132.4, 132.3, 129.7, 128.6, 128.6, 128.4, 127.7, 125.9, 105.8, 49.8, 21.6, 21.6. HRMS (ESI) m/z calculated for $\text{C}_{22}\text{H}_{20}\text{N}_4\text{O}_3\text{S}$ $[\text{M} + \text{H}]^+$ 421.1329, found 421.1332.




7-(Thiophen-2-yl)-3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (**19a**):

Following the general procedure, 5-tosyl-5*H*-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25 mmol) was converted to 7-(Thiophen-2-yl)-3-tosyl-3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazine (40

mg, 41%). The resulting crystalline orange solid was isolated after column chromatography using a 2→10% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.82 (s, 1H), 8.09 (m, 2H), 7.97 (s, 1H), 7.74 (d, *J* = 3.9, 1H), 7.52 (dd, *J* = 3.6, 1.1 Hz, 1H), 7.35 (dd, *J* = 5.0, 1.1 Hz, 1H), 7.31 (m, 2H), 7.11 (dd, *J* = 5.0, 3.6 Hz, 1H), 6.75 (d, *J* = 3.9 Hz, 1H), 2.38 (s, 3H). ¹³C NMR (176 MHz, CDCl₃), δ: 145.9, 142.8, 139.6, 136.5, 136.3, 134.8, 133.1, 129.9, 128.2, 127.9, 126.0, 124.7, 123.8, 118.1, 106.8, 98.4, 21.7. HRMS (ESI) *m/z* calculated for C₁₉H₁₄N₄O₂S₂ [M + H]⁺ 395.0631, found 395.0628. mp 205-207 °C.



1-(Thiophen-2-yl)-2-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (**19b**):

Following the general procedure, 5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-amine (72 mg, 0.25 mmol) was converted to 1-(Thiophen-2-yl)-2-((5-tosyl-5H-pyrrolo[2,3-*b*]pyrazine-2-yl)amino)ethan-1-one (10 mg, 10%). The resulting crystalline white solid was isolated after column chromatography using a 5→40% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 7.98 (m, 2H), 7.90 (dd, *J* = 3.8, 1.1 Hz, 1H), 7.84 (s, 1H), 7.75 (d, *J* = 4.0 Hz, 1H), 7.72 (dd, *J* = 4.9, 1.1 Hz), 7.27 (m, 2H), 7.19 (dd, *J* = 4.9, 3.8 Hz, 1H), 6.56 (d, *J* = 4.0 Hz, 1H), 5.57 (t, *J* = 4.5 Hz, 1H), 4.83 (d, *J* = 4.5 Hz, 2H), 2.37 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ: 188.2, 151.9, 145.3, 141.1, 138.6, 135.3, 134.9, 134.4, 132.3, 129.7, 128.5, 128.5, 128.4, 127.7, 105.8, 48.3, 21.6. HRMS (ESI) *m/z* calculated for C₁₉H₁₆N₄O₃S₂ [M + H]⁺ 413.0737, found 413.0737. mp 200 °C (decomp).



2-Phenylimidazo[1,2-*a*]pyridine (25a):


Following the general procedure, 2-aminopyridine (108 mg, 1.15 mmol) was converted to 2-Phenylimidazo[1,2-*a*]pyridine (179 mg, 92%). The resulting crystalline tan solid was isolated after column chromatography using a 2→10% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.09 (dt, *J* = 6.8, 1.2 Hz, 1H), 7.95 (m, 2H), 7.84 (s, 1H), 7.62 (dt, *J* = 9.1, 1.2 Hz, 1H), 7.43 (m, 2H), 7.33 (m, 1H), 7.15 (ddd, *J* = 9.1, 6.7, 1.2 Hz, 1H), 6.75 (td, *J* = 6.7, 1.2 Hz, 1H). ¹³C NMR (176 MHz, CDCl₃) δ: 145.7, 145.6, 133.7, 128.7, 128.0, 126.0, 125.6, 124.7, 117.5, 112.4, 108.1. HRMS (ESI) *m/z* calculated for C₁₃H₁₀N₂ [M + H]⁺ 195.0917, found 195.0919. mp 132-134 °C.

**2-Phenylimidazo[1,2-*a*]quinoline (26a):**

Following the general procedure, 2-aminoquinoline (36 mg, 0.25 mmol) was converted to 2-Phenylimidazo[1,2-*a*]quinoline (40 mg, 66%). The resulting crystalline yellow solid was isolated after column chromatography using a 2→10% gradient of EtOAc in CH₂Cl₂.


¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.33 (s, 1H), 8.01 (m, 2H), 7.96 (d, *J* = 8.4 Hz, 1H), 7.82 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.66 (ddt, *J* = 8.4, 7.1, 1.3 Hz, 1H), 7.60 (d, *J* = 9.4 Hz, 1H), 7.53 (dd, *J* = 9.4, 1.1 Hz, 1H), 7.48 (m, 1H), 7.47 (m, 2H), 7.34 (m, 1H). ¹³C NMR (176 MHz, CDCl₃) δ: 144.9, 144.2, 133.8, 132.5, 129.2, 128.8, 128.7, 127.8, 126.3, 125.8, 124.7, 123.4, 117.1, 115.1, 106.7. HRMS (ESI) *m/z* calculated for C₁₇H₁₂N₂ [M + H]⁺ 245.1074, found 245.1077. mp 103-105 °C.



6-Methyl-2-phenylimidazo[1,2-*a*]pyrazine (**27a**):

Following the general procedure, 2-amino-5-methylpyrazine (27 mg, 0.25 mmol) was converted to 6-Methyl-2-phenylimidazo[1,2-*a*]pyrazine (33 mg, 63%). The resulting crystalline tan solid was isolated after column chromatography using a 2→10% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 9.03 (br s, 1H), 7.96 (m, 2H), 7.88 (t, *J* = 1.2 Hz, 1H), 7.86 (s, 1H), 7.46 (m, 2H), 7.38 (m, 1H), 2.52 (d, *J* = 1.2 Hz, 3H). ¹³C NMR (176 MHz, CDCl₃) δ: 147.7, 142.4, 139.9, 138.4, 132.9, 128.8, 128.7, 126.2, 115.6, 108.8, 20.8. HRMS (ESI) *m/z* calculated for C₁₃H₁₁N₃ [M + H]⁺ 210.1026, found 210.1025. mp 171-173 °C.




2-((5-Methylpyrazin-2-yl)amino)-1-phenylethan-1-one (**27b**):

Following the general procedure, 2-amino-5-methylpyrazine (27 mg, 0.25 mmol) was converted to 2-((5-Methylpyrazin-2-yl)amino)-1-phenylethan-1-one (4 mg, 6%). The resulting amorphous orange solid was isolated after column chromatography using a 2→10% gradient of EtOAc in CH₂Cl₂.

¹H NMR (700 MHz, CDCl₃), δ (mult., *J*, nH): 8.07 (m, 2H), 8.02 (d, *J* = 1.5 Hz, 1H), 7.90 (br s, 1H), 7.63 (td, *J* = 7.3, 1.3 Hz, 1H), 7.52 (m, 2H), 5.58 (br t, *J* = 4.3 Hz, 1H), 4.87 (d, *J* = 4.3 Hz, 2H), 2.40 (s, 3H). ¹³C NMR (176 MHz, CDCl₃) δ: 195.0,

151.8, 141.2, 140.4, 134.7, 134.0, 132.3, 128.9, 127.9, 48.1, 20.1. HRMS (ESI) m/z calculated for $C_{13}H_{13}N_3O$ $[M + H]^+$ 228.1132, found 228.1132.



2-Phenylimidazo[1,2-*a*]pyrimidine (**28a**):

Following the general procedure, 2-aminopyrimidine (24 mg, 0.25 mmol) was converted to 2-Phenylimidazo[1,2-*a*]pyrimidine (33 mg, 68%). The resulting crystalline orange solid was isolated after column chromatography using a 2→10% gradient of EtOAc in CH_2Cl_2 .

1H NMR (700 MHz, $CDCl_3$), δ (mult., J , nH): 8.53 (dd, J = 4.1, 2.0 Hz, 1H), 8.43 (dd, J = 6.7, 2.0 Hz, 1H), 8.04 (m, 2H), 7.83 (s, 1H), 7.46 (m, 2H), 7.37 (m, 1H), 6.86 (dd, J = 6.7, 4.1 Hz, 1H). ^{13}C NMR (176 MHz, $CDCl_3$) δ : 149.7, 149.0, 147.4, 133.1, 132.8, 128.7, 128.6, 126.3, 108.7, 106.0. HRMS (ESI) m/z calculated for $C_{12}H_9N_3$ $[M + H]^+$ 196.0870, found 196.0865. mp 187-190 °C.

Acknowledgements

The design, study conducted, analysis and financial support of the study were provided by AbbVie. Vincent S. Chan, Jose G. Napolitano, Scott W. Krabbe and Shashank Shekhar are AbbVie employees. Alicia Phelps and Jennifer Schomaker are employees of University of Wisconsin, Madison and were also involved in the discussion, reviewing, and approving of the publication; they have not received any personal compensation from AbbVie. The NMR and Mass Spectrometry facilities are funded by the NSF (CHE-9974839, CHE-9304546, CHE-9208463, CHE-9629688) and the University of Wisconsin, as well as the NIH (RR08389-01).

Supporting Information Available: ^1H , and ^{13}C spectra of all compounds reported in the manuscript, complete optimization of reaction conditions for the formation of **9a** and investigation of insertion of Ir into **8** by mass spectroscopy.

References

- (1) Baldwin, J. E.; Adlington, R. M.; Godfrey, C. R. A.; Gollins, D. W.; Vaughan, J. G. *J. Chem. Soc., Chem. Commun.* **1993**, 1434.
- (2) Mangion, I. K.; Nwamba, I. K.; Shevlin, M.; Huffman, M. A. *Org. Lett.* **2009**, *11*, 3566.
- (3) Burtoloso, A. C. B.; Dias, R. M. P.; Leonarczyk, I. A. *Eur. J. Org. Chem.* **2013**, *2013*, 5005.
- (4) See references 5 to 8 for examples of metal-carbene complexes generated from sulfonium ylides.
- (5) Trost, B. M. *J. Am. Chem. Soc.* **1966**, *88*, 1587.
- (6) Cohen, T.; Herman, G.; Chapman, T. M.; Kuhn, D. *J. Am. Chem. Soc.* **1974**, *96*, 5627.
- (7) Cimetière, B.; Julia, M. *Synlett* **1991**, *1991*, 271.
- (8) Gandelman, M.; Naing, K. M.; Rybtchinski, B.; Poverenov, E.; Ben-David, Y.; Ashkenazi, N.; Gauvin, R. M.; Milstein, D. *J. Am. Chem. Soc.* **2005**, *127*, 15265.
- (9) Jellema, E.; Jongerius, A. L.; Reek, J. N. H.; de Bruin, B. *Chem. Soc. Rev.* **2010**, *39*, 1706.
- (10) Mangion, I. K.; Weisel, M. *Tetrahedron Lett.* **2010**, *51*, 5490.
- (11) Mangion, I. K.; Ruck, R. T.; Rivera, N.; Huffman, M. A.; Shevlin, M. *Org. Lett.* **2011**, *13*, 5480.
- (12) Molinaro, C.; Bulger, P. G.; Lee, E. E.; Kosjek, B.; Lau, S.; Gauvreau, D.; Howard, M. E.; Wallace, D. J.; O'Shea, P. D. *J. Org. Chem.* **2012**, *77*, 2299.
- (13) Suarez, A. I. O.; del Río, M. P.; Remerie, K.; Reek, J. N. H.; de Bruin, B. *ACS Catalysis* **2012**, *2*, 2046.
- (14) Xiao, Q.; Zhang, Y.; Wang, J. *Acc. Chem. Res.* **2013**, *46*, 236.
- (15) Doyle, M. P. *Acc. Chem. Res.* **1986**, *19*, 348.
- (16) Doyle, M. P. *Chem. Rev.* **1986**, *86*, 919.
- (17) Davies, H. M. L.; Beckwith, R. E. *J. Chem. Rev.* **2003**, *103*, 2861.
- (18) Doyle, M. P.; McKervy, M. A.; Ye, T. *Modern Catalytic Methods for Organic Synthesis with Diazo Compounds*; Wiley-Interscience: New York, 1998.
- (19) Moore, J. A.; Reed, D. E. *Org. Synth.* **1961**, *41*, 16.
- (20) Bio, M. M.; Javadi, G.; Song, Z. *J. Synthesis* **2005**, 19.
- (21) See references xx and yy for the use of diazo compounds on manufacturing scale.
- (22) Salzmann, T. N.; Ratcliffe, R. W.; Christensen, B. G.; Bouffard, F. A. *J. Am. Chem. Soc.* **1980**, *102*, 6161.
- (23) Reider, P. J.; Grabowski, E. J. *J. Tetrahedron Lett.* **1982**, *23*, 2293.
- (24) Wishart, N.; Argiriadi, M. A.; Calderwood, D. J.; Ericsson, A. M.; Fiamengo, B. R.; Frank, K. E.; Friedman, M.; George, D. M.; Goedken, E. R.; Josephsohn, N. S. *U. S. Pat. Appl.* **2011**, US20110311474 A1 20111222.
- (25) Wishart, N.; Argiriadi, M. A.; Calderwood, D. J.; Ericsson, A. M.; Fiamengo, B. A.; Frank, K. E.; Friedman, M.; George, D. M.; Goedken, E. R.; Josephsohn, N. S. *PCT Int. Appl.* **2011**, WO 2011068881 A1 20110609.
- (26) Van Epps, S.; Fiamengo, B.; Edmunds, J.; Ericsson, A.; Frank, K.; Friedman, M.; George, D.; George, J.; Goedken, E.; Kotecki, B.; Martinez, G.; Merta, P.; Morytko, M.; Shekhar, S.; Skinner, B.; Stewart, K.; Voss, J.; Wallace, G.; Wang, L.; Wang, L.; Wishart, N. *Bioorganic & Medicinal Chemistry Letters* **2013**, *23*, 693.
- (27) In situ generated alpha-halo ketones and alpha-tosyloxy ketones have been widely used for the synthesis of other imidazo-fused heterocycles; see references 28 and 29 for recent reviews. See reference 30 for an application of alpha-diazoketones for the synthesis of imidazo[1,2-a]pyridines.
- (28) Pericherla, K.; Kaswan, P.; Pandey, K.; Kumar, A. *Synthesis* **2015**, *47*, 887.
- (29) Bagdi, A. K.; Santra, S.; Monir, K.; Hajra, A. *Chem. Commun.* **2015**, *51*, 1555.

- (30) Yadav, J. S.; Subba Reddy, B. V.; Gopal Rao, Y.; Srinivas, M.; Narsaiah, A. V. *Tetrahedron Lett.* **2007**, 48, 7717.
- (31) DMSO was found to inhibit Rh-catalyzed reaction of aniline with sulfoxonium ylide; see reference 2.
- (32) See Table S1 in the supporting information.
- (33) See Table S1 for effect of other counter anions and solvents on the reaction.
- (34) See footnote 16 in reference 9.
- (35) See reference 8 for evidence for the generation of metallocarbenes from reaction of sulfur ylides with Rh- and Ir-complexes.
- (36) Gunther, H. *NMR Spectroscopy: Basic Principles, Concepts and Applications in Chemistry*; 3rd ed.; Wiley-VCH Verlag GmbH & Co. (Weinheim, Germany).
- (37) The ^{15}N NMR signal for **a** was observed at -317 ppm. This chemical shift is in the region expected for the nitrogen atom in -NH₂.
- (38) Formation of the Ir-carbon bond by substitution of chloride on the Ir catalyst by sulfoxonium ylide, as proposed by Shea and co-workers (see references 9 and 14), cannot be ruled out based on the available data. See Figure S1 for an alternative reaction mechanism. The impact of ligand on the selectivity of the reaction remains the same irrespective of the mechanism of formation of the Ir-carbon bond.
- (39) The β -keto amine **9b** was the only product obtained in the stoichiometric reaction, no **9a** was observed.
- (40) Armarego, W. L. F.; Chai, C. L. L. *Purification of Laboratory Chemicals*; 6 ed.; Elsevier Burlington, MA, 2009.
- (41) Still, W. C.; Kahn, M.; Mitra, A. *J. Org. Chem.* **1978**, 43, 2923.
- (42) Napolitano, J. G.; Lankin, D. C.; McAlpine, J. B.; Niemitz, M.; Korhonen, S.-P.; Chen, S.-N.; Pauli, G. F. *J. Org. Chem.* **2013**, 78, 9963.